Tenaya Therapeutics, Inc. (TNYA) intrinsic value & 10-year financials
Tenaya Therapeutics, Inc. (TNYA) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.38
- Market cap
- $58.3M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -89.8%
- Free cash flow (FY2025)
- -$68.9M
TNYA 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$90.6M | -$0.59 | -$68.9M | — | -143.7% |
| FY2024 | — | -$111.1M | -$1.31 | -$91.5M | — | -115.3% |
| FY2023 | — | -$124.1M | -$1.68 | -$103.3M | — | -100.5% |
| FY2022 | — | -$123.7M | -$2.76 | -$125.1M | — | -60.8% |
| FY2021 | — | -$72.7M | -$4.10 | -$85.9M | — | -28.7% |
| FY2020 | — | -$38.4M | — | -$45.2M | — | — |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Tenaya Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Tenaya Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -89.8% ROIC.
Tenaya Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Tenaya Therapeutics, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.